1. Home
  2. ENTX vs PDSB Comparison

ENTX vs PDSB Comparison

Compare ENTX & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • PDSB
  • Stock Information
  • Founded
  • ENTX 2010
  • PDSB 2005
  • Country
  • ENTX Israel
  • PDSB United States
  • Employees
  • ENTX N/A
  • PDSB N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • PDSB Biotechnology: Pharmaceutical Preparations
  • Sector
  • ENTX Health Care
  • PDSB Health Care
  • Exchange
  • ENTX Nasdaq
  • PDSB Nasdaq
  • Market Cap
  • ENTX 69.6M
  • PDSB 58.7M
  • IPO Year
  • ENTX 2018
  • PDSB N/A
  • Fundamental
  • Price
  • ENTX $1.67
  • PDSB $1.08
  • Analyst Decision
  • ENTX Strong Buy
  • PDSB Strong Buy
  • Analyst Count
  • ENTX 1
  • PDSB 3
  • Target Price
  • ENTX $10.00
  • PDSB $10.00
  • AVG Volume (30 Days)
  • ENTX 46.7K
  • PDSB 778.4K
  • Earning Date
  • ENTX 03-28-2025
  • PDSB 03-27-2025
  • Dividend Yield
  • ENTX N/A
  • PDSB N/A
  • EPS Growth
  • ENTX N/A
  • PDSB N/A
  • EPS
  • ENTX N/A
  • PDSB N/A
  • Revenue
  • ENTX $181,000.00
  • PDSB N/A
  • Revenue This Year
  • ENTX N/A
  • PDSB $5,518.68
  • Revenue Next Year
  • ENTX N/A
  • PDSB N/A
  • P/E Ratio
  • ENTX N/A
  • PDSB N/A
  • Revenue Growth
  • ENTX N/A
  • PDSB N/A
  • 52 Week Low
  • ENTX $1.41
  • PDSB $1.08
  • 52 Week High
  • ENTX $3.35
  • PDSB $4.42
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 32.36
  • PDSB 34.25
  • Support Level
  • ENTX $1.85
  • PDSB $1.19
  • Resistance Level
  • ENTX $2.02
  • PDSB $1.41
  • Average True Range (ATR)
  • ENTX 0.11
  • PDSB 0.10
  • MACD
  • ENTX -0.01
  • PDSB -0.01
  • Stochastic Oscillator
  • ENTX 10.87
  • PDSB -6.06

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About PDSB PDS Biotechnology Corporation

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Share on Social Networks: